610

610 is a **recombinant humanized monoclonal antibody** of the IgG1 type specifically targeting **interleukin-5 (IL-5)**[6][4]. It inhibits IL-5 by blocking its interaction with the IL-5 receptor, thereby reducing the activity of eosinophils, a critical cell type in the pathogenesis of asthma and certain autoimmune disorders[6][1][3][4][5]. 610 is being developed primarily for the treatment of **asthma**, especially severe eosinophilic asthma, and is also under investigation for autoimmune disorders[1][5]. Developed in China by Sunshine Guojian Pharmaceutical and 3SBio, the drug is in phase 2 and phase 3 clinical trials with a focus on efficacy, pharmacokinetics, safety, and immunogenicity in adults with severe asthma[1][5][8].

Other names

610 anti-IL5 antibodyRecombinant anti-IL-5 humanized monoclonal antibody